Zymedyne’s drug development program targets Cav3.2 T-type calcium channels which are critical contributors to the transmission of pain signals in the afferent pain pathway.  In a wide range of chronic pain conditions these channels are aberrantly upregulated. Work conduced in the Zamponi laboratory revealed that this enhancement is due to a pathological upregulation of the expression of the deubiquitinating enzyme USP5 which associates with the Cav3.2 channels to prevent their degradation.  Zymedyne has a proprietary high throughout screen for small organic disruptors of USP5 binding to Cav3.2, and generated a series of small molecules which inhibit this interaction with high selectivity and affinity, resulting in enhanced degradation of the channels and thus analgesia. Zymedyne’s molecules are highly efficacious in mouse models of acute and chronic inflammatory pain, and in different modalities of neuropathic pain, with no development of tolerance in repeat dosing paradigms.  In addition the mechanism has been independently verified in rats at UC Denver. They key advantage of Zymedyne’s approach is that it targets only those channels that are aberrantly upregulated by USP5, while sparing the normal channel function in other tissues, thus reducing the risk of adverse effects. Zymedyne is now poised to advance one lead molecule to IND enabling studies.


Discovery of USP5 as a Cav3.2 interacting protein in Zamponi lab (University of Calgary)
Filing of USP5 provisional patent application
​ Start of collaboration with Center for Drug Research and Development (CDRD)​. Development of HTS and initial hits from screen. ​ CDRD funding from Pfizer Innovation Fund secured
Completion of compound screening at CDRD (175,000 compounds). ​ Alberta Pfizer Translational Grant to Zamponi laboratory ($180K)
SAR studies on library hits completed (not pursued further) 
CDRD Funding (Merck/CDRD/IRIC) for compound library screening secured
Alberta Innovates-Tech Futures Grant to Zamponi laboratory ($450 K)
Library screen of 40,000 compounds completed (potential leads identified). ​ USP5 mechanism US patent issued
Formation of Zymedyne Therapeutics by Dr. Zamponi and Dr. Bladen​. Innovate Calgary Fellowship secured ($200 K). IP assigned to Zymedyne​. UCeed Investment Funding secured ($125 K in two tranches)​. Campus Alberta Neuroscience Funding Secured ($30 K)​. US Provisional patent on thiazolidine derivatives filed.
Alberta Innovates AICE grant secured ($ 600 K)​. Parex Innovation Fellowship secured ($22 K)​
​ Alberta Innovates Engineering for Human and Animal Health Prize ($10 K). 2 Mitacs Fellowships secured.
US Provisional patent on THQ compound series filed​. ~90 derivatives synthesized and tested, PK/ADME completed​. Mitacs Fellow Dr. Ketul Patel receives Mitacs Award for Outstanding Innovation. ​ Zymedyne wins Challenger Award in TMRRW Awards competition (Australia).
Lead compound for IND studies selected
Previous slide
Next slide